Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
Vertex Pharmaceuticals, Inc. Logo

Combined Holdings of Vertex Pharmaceuticals (VRTX) - Updated Daily

Lock IconJoin Premium Plan
The Bucket Report Icon
Download ARK WatchlistsDownload ARK holdings as watchlists that can be imported into TradingView and Interactive Brokers
Date
Direction
Shares
Fund Weight
Fund
May 19, 2022SELL5.446k0.0555%ARKG
April 29, 2022SELL24.485k0.2474%ARKG
April 13, 2022SELL11.746k0.1%ARKG
March 31, 2022SELL57.709k0.398%ARKG
March 28, 2022SELL4.771k0.0343%ARKG

Key Statistics

DateMay 05, 2022Revenue
Expected0
Actual$2.10b
EPS
Expected$3.49
Actual$3.52
🕵🏼Found In🏷Last Price
ARKG$258.59
⚖️Weighting🧢Market Cap
0.63%$66.14b
🏋️‍♀️Weight Rank Across All Funds🧮Price to Sales
348.32
💳ARK Estimated Cost Average🌏Country
$225.49 - ARKG
🇺🇸United States
🎫ARK Ownership Percent
0.15%
Description
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Website
www.vrtx.com